O. Naumova, Inna V. Gogunska, T. V. Smagina, Vladislav I. Nesterchuk, T. Kholodenko
{"title":"The role of beta-glucans in combined therapy of patients with seasonal allergic rhinitis","authors":"O. Naumova, Inna V. Gogunska, T. V. Smagina, Vladislav I. Nesterchuk, T. Kholodenko","doi":"10.37219/2528-8253-2021-3-45","DOIUrl":null,"url":null,"abstract":"Topicality: Beta-glucans are a group of biologically active polysaccharides of natural origin with a proven pleiotropic immunomodulatory effect. In vitro experiments as well as animal and human clinical studies proved the importance of beta-glucans in the treatment and prevention of allergic diseases. This opens up new prospects for the use of this widespread and popular group of natural substances.\nAim: to investigate whether the addition of \"Bewell®\" can alleviate the symptoms of seasonal AR in children\nsensitized to ragweed during flowering and improve their quality of life.\nMaterials and methods: The study involved 30 patients (12 girls, 18 boys) aged from 6 to 12 years with a verified diagnosis of seasonal allergic rhinitis. Clinical manifestations of rhinoconjunctivitis were evaluated according to T5SS scale, quality of life (QOL) – according to Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ).\nResults: The study found that administration of \"Bewell®\" in the complex therapy of seasonal allergic rhinitis significantly reduced rhinoconjunctival manifestations (p<0.001). The surveyed patients reduced consumption of antihistamines. After a treatment course, a decrease in the PRQLQ score was detected for such parameters as: irritability, need to wake up at night due to nasal congestion, need to take medications to relieve AR symptoms such as antihistamines or inhaled corticosteroids, which indicated an increase in the quality of life of patients after the therapy.\nThe use of a complex of parameters to evaluate the therapy effectiveness showed that the use of beta-1,3/1,6-glucan (\"Bewell®\") is promising for reducing AR symptoms in children, leading to their rapid regression, improving the quality of life and effective relief of AR symptoms. Administration of \"Bewell®\" reduces the need for concomitant therapy and helps to reduce the drug load.","PeriodicalId":19612,"journal":{"name":"OTORHINOLARYNGOLOGY No3(4) 2021","volume":"59 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OTORHINOLARYNGOLOGY No3(4) 2021","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37219/2528-8253-2021-3-45","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Topicality: Beta-glucans are a group of biologically active polysaccharides of natural origin with a proven pleiotropic immunomodulatory effect. In vitro experiments as well as animal and human clinical studies proved the importance of beta-glucans in the treatment and prevention of allergic diseases. This opens up new prospects for the use of this widespread and popular group of natural substances.
Aim: to investigate whether the addition of "Bewell®" can alleviate the symptoms of seasonal AR in children
sensitized to ragweed during flowering and improve their quality of life.
Materials and methods: The study involved 30 patients (12 girls, 18 boys) aged from 6 to 12 years with a verified diagnosis of seasonal allergic rhinitis. Clinical manifestations of rhinoconjunctivitis were evaluated according to T5SS scale, quality of life (QOL) – according to Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ).
Results: The study found that administration of "Bewell®" in the complex therapy of seasonal allergic rhinitis significantly reduced rhinoconjunctival manifestations (p<0.001). The surveyed patients reduced consumption of antihistamines. After a treatment course, a decrease in the PRQLQ score was detected for such parameters as: irritability, need to wake up at night due to nasal congestion, need to take medications to relieve AR symptoms such as antihistamines or inhaled corticosteroids, which indicated an increase in the quality of life of patients after the therapy.
The use of a complex of parameters to evaluate the therapy effectiveness showed that the use of beta-1,3/1,6-glucan ("Bewell®") is promising for reducing AR symptoms in children, leading to their rapid regression, improving the quality of life and effective relief of AR symptoms. Administration of "Bewell®" reduces the need for concomitant therapy and helps to reduce the drug load.